Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease

Kim, Sung Tae; Son, Hyo Jin; Choi, Ji Hyun; Ji, In Jung; Hwang, Onyou

doi:10.1016/j.brainres.2009.09.103

Cited by 77 publications

(68 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase in muscle rigidity and hypokinesia may cause remarkable decrease of stride length and swing speed in PD rats [14], which is similar to the clinical signs that is often seen in PD patients that they usually take smaller steps when trying to walk [15]. The measurement of stance, step cycle and duty cycle was increased in the severely impaired groups of rats of the study due mainly to the longer contact between the paws and the glass plate [16].…”

Section: Quantitative Assessment Of Gaitmentioning

confidence: 69%

Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease

Zhou

Zhang

Chang³

et al. 2015

Neuroscience Letters

View full text Add to dashboard Cite

Section: Quantitative Assessment Of Gaitmentioning

confidence: 69%

Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease

Zhou

Zhang

Chang³

et al. 2015

Neuroscience Letters

View full text Add to dashboard Cite

“…A speed of 13 cm/ sec may be more comparable to voluntary ground walking as opposed to forced walking at 24 cm/sec. Studies that have assessed voluntary ground walking via the stepping test in MPTP-treated mice have observed decreased stride length (Kim et al, 2010;Viaro et al, 2010;Zhao et al, 2010) and greater stride length variability (Kurtz et al, 2007). In PD patients, Frenkel-Toledo and colleagues (2005) have shown a decrease in gait variability during forced walking on a treadmill.…”

Section: Progressive Mptp Leads To Lasting Changes In Multiple Gait Dmentioning

confidence: 97%

Profiling changes in gait dynamics resulting from progressive 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced nigrostriatal lesioning

Goldberg

Hampton

McCue

et al. 2011

J of Neuroscience Research

View full text Add to dashboard Cite

Current behavioral measurements for motor impairment are not consistently sensitive in rodent models of partial nigrostriatal dopamine (DA) depletion. In addition to exploratory and somatosensory behavior, motor skills that are thought to be directly translatable to human Parkinson's disease patients are assessed. However, many of these motor tests require the training and learning of particular tasks, so it cannot be determined whether impairments are due to motor or to learning deficit. Therefore, we have quantified multiple temporal and spatial indices of gait dynamics in a model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced partial nigrostriatal lesioning using a treadmill apparatus requiring no prior training. Three days following the cessation of progressively increased MPTP administration, rearing and foot-fault behaviors showed significant deficit. Ten days after the final MPTP injection, gait dynamics were assessed and indicated differences between MPTP- and vehicle-treated animals. The major significant changes were in stride length, frequency, duration, and number of steps. Three weeks following a progressively increased dose of MPTP (administered 5 days per week over the course of 4 weeks), mice showed a 63% decrease in tyrosine hydroxylase-immunoreactive (TH-ir) nigrostriatal neurons in the substantia nigra pars compacta and a 72% decrease in TH-ir terminals in the caudate-putamen. This suggests that there is a continued effect of progressively increased MPTP on nigrostriatal DA neurons, correlated with rearing and foot-fault behaviors and further characterized by differences in temporal and spatial measurements of gait dynamics.

show abstract

“…Also MPTP models lack the behavioral deficits apparent on standard motor mouse tests [Kim et al 2010]. …”

Section: Introductionmentioning

confidence: 99%

Natural toxins implicated in the development of Parkinson’s disease

Salama¹,

Arias-Carrión²

2011

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect; each has its own limitations. Based on epidemiological data, a new trend of using environmental toxins in PD modeling seems attractive and has dominated public discussions of the disease etiology. A search for new environmental toxin-based models would improve our knowledge of the pathology of the condition. Here, we discuss some toxins of natural origin (e.g. cycad-derived toxins, epoxomicin, Nocardia asteroides bacteria, Streptomyces venezuelae bacteria, annonacin and DOPAL) that possibly represent a contributory environmental component to PD.

show abstract

Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease

Cited by 77 publications

References 29 publications

Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease

Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease

Profiling changes in gait dynamics resulting from progressive 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced nigrostriatal lesioning

Natural toxins implicated in the development of Parkinson’s disease

Contact Info

Product

Resources

About